Granules India Limited has announced the signing of an agreement to acquire Senn Chemicals AG, a Swiss-based Contract Development and Manufacturing Organization (CDMO) specializing in peptides. The acquisition, expected to close in the first half of 2025, will enhance Granules’ capabilities in peptide-based therapeutics and expand its presence in the global CDMO market.
Senn Chemicals brings expertise in Liquid-Phase Peptide Synthesis (LPPS) and Solid-Phase Peptide Synthesis (SPPS), along with a robust CDMO business and established customer relationships across pharmaceuticals, cosmetics, amino acid derivatives (AAD), and theragnostic segments. Its ISO 9001:2015-certified facility, approved for cGMP production by Swissmedic, ensures compliance with global regulatory standards, including FDA recognition under the Mutual Recognition Agreement (MRA).
This strategic move aligns with Granules’ vision to enter the high-growth peptide-based anti-diabetic and anti-obesity markets, including GLP-1 receptor agonists. The companies are already collaborating on two GLP-1-based APIs, with plans to expand their peptide portfolio using Senn’s R&D capabilities.
By leveraging Senn’s European presence, Granules aims to strengthen its global footprint, access a skilled R&D talent pool, and cater to regulated markets. The acquisition also marks Granules’ entry into the CDMO segment, combining Senn’s innovation-driven peptide platform with Granules’ expertise in large-scale, cost-efficient manufacturing.
This integration positions Granules as a key player in the development and manufacturing of peptide-based applications across pharmaceuticals, cosmetics, and theragnostic industries, spanning the entire value chain from AADs to peptide-based active ingredients.
